[go: up one dir, main page]

IL282465B2 - 4/91 IBV vaccine with heterologous spike protein - Google Patents

4/91 IBV vaccine with heterologous spike protein

Info

Publication number
IL282465B2
IL282465B2 IL282465A IL28246521A IL282465B2 IL 282465 B2 IL282465 B2 IL 282465B2 IL 282465 A IL282465 A IL 282465A IL 28246521 A IL28246521 A IL 28246521A IL 282465 B2 IL282465 B2 IL 282465B2
Authority
IL
Israel
Prior art keywords
ibv
immunogenic composition
protein
heterologous
fragment
Prior art date
Application number
IL282465A
Other languages
English (en)
Hebrew (he)
Other versions
IL282465A (en
IL282465B1 (en
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of IL282465A publication Critical patent/IL282465A/en
Publication of IL282465B1 publication Critical patent/IL282465B1/en
Publication of IL282465B2 publication Critical patent/IL282465B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL282465A 2018-10-31 2019-10-28 4/91 IBV vaccine with heterologous spike protein IL282465B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18203626 2018-10-31
PCT/EP2019/079389 WO2020089164A1 (en) 2018-10-31 2019-10-28 4/91 ibv vaccine with heterologous spike protein

Publications (3)

Publication Number Publication Date
IL282465A IL282465A (en) 2021-06-30
IL282465B1 IL282465B1 (en) 2024-12-01
IL282465B2 true IL282465B2 (en) 2025-04-01

Family

ID=64048879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282465A IL282465B2 (en) 2018-10-31 2019-10-28 4/91 IBV vaccine with heterologous spike protein

Country Status (14)

Country Link
US (2) US11224649B2 (es)
EP (1) EP3873516A1 (es)
JP (1) JP7206383B2 (es)
KR (1) KR20210087058A (es)
CN (2) CN112996537B (es)
AR (1) AR116876A1 (es)
BR (1) BR112021008440A2 (es)
CO (1) CO2021005066A2 (es)
EA (1) EA202191145A1 (es)
IL (1) IL282465B2 (es)
MX (1) MX2021004907A (es)
MY (1) MY207126A (es)
UA (1) UA129674C2 (es)
WO (1) WO2020089164A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013743A (es) 2019-05-10 2021-12-10 Boehringer Ingelheim Vetmedica Gmbh Subunidad s1 modificada de la proteina de espicula de coronavirus.
JP2023549787A (ja) * 2020-11-12 2023-11-29 インターベット インターナショナル ベー． フェー． キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
WO2025027551A2 (en) 2023-08-03 2025-02-06 Boehringer Ingelheim Vetmedica Gmbh Ibv vaccine with heterologous dmv/1639 spike protein
CN117737298B (zh) * 2023-09-22 2024-06-25 江苏农牧科技职业学院 同时鉴别不同基因型禽传染性支气管炎病毒的多重pcr引物、检测试剂、方法及应用
CN118546258B (zh) * 2024-06-03 2024-11-29 中国动物卫生与流行病学中心 一种鸡传染性支气管炎病毒抗原表位融合肽及其在间接elisa检测中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
PT639640E (pt) * 1993-07-30 2001-03-30 Akzo Nobel Nv Vacina para aves domesticas com infeccoes provocadas pela estirpe 4/91 do virus da bronquite
JP2003503039A (ja) * 1999-06-25 2003-01-28 マキシジェン， インコーポレイテッド 弱毒化したワクチンの操作のための方法および組成物
PT1259257E (pt) 2000-02-29 2010-06-01 Wyeth Llc Protecção in ovo contra a bronquite infecciosa
SI1610817T1 (sl) 2003-03-03 2010-01-29 Intervet Int Bv Virus infekcijskega bronhitisa s spremenjenim spike genom
CN1917900A (zh) * 2003-10-30 2007-02-21 勃林格殷格翰动物保健有限公司 猪红斑丹毒丝菌－副猪嗜血菌疫苗及其使用方法
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
AR072976A1 (es) * 2008-08-08 2010-10-06 Wyeth Corp Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
GB0911794D0 (en) * 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
US20140141043A1 (en) * 2012-11-16 2014-05-22 Auburn University Compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
US9764025B2 (en) * 2014-10-20 2017-09-19 Auburn University Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced
MX2017010908A (es) * 2015-02-26 2017-12-07 Boehringer Ingelheim Vetmedica Gmbh Vacuna bivalente contra el virus de gripe porcina.
CN109641043A (zh) * 2016-06-16 2019-04-16 勃林格殷格翰动物保健有限公司 针对感染性支气管炎病毒的疫苗
US20190358316A1 (en) * 2017-02-06 2019-11-28 University Of Maryland, College Park Infectious bronchitis virus vaccine using newcastle disease viral vector
US10772953B2 (en) * 2017-08-09 2020-09-15 Auburn University Recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID CAVANAGH ET AL:, VARIATION IN THE SPIKE PROTEIN OF THE 793/B TYPE OF INFECTIOUS BRONCHITIS VIRUS, IN THE FIELD AND DURING ALTERNATE PASSAGE IN CHICKENS AND EMBRYONATED EGGS, 1 February 2005 (2005-02-01) *
MARIA ARMESTO ET AL:, A RECOMBINANT AVIAN INFECTIOUS BRONCHITIS VIRUS EXPRESSING A HETEROLOGOUS SPIKE GENE BELONGING TO THE 4/91 SEROTYPE, 30 August 2011 (2011-08-30) *
SAMANTHA ELLIS ET AL:, RECOMBINANT INFECTIOUS BRONCHITIS VIRUSES EXPRESSING CHIMERIC SPIKE GLYCOPROTEINS INDUCE PARTIAL PROTECTIVE IMMUNITY AGAINST HOMOLOGOUS CHALLENGE DESPITE LIMITED REPLICATION IN VIVO., 12 September 2018 (2018-09-12) *
T. HODGSON ET AL:, RECOMBINANT INFECTIOUS BRONCHITIS CORONAVIRUS BEAUDETTE WITH THE SPIKE PROTEIN GENE OF THE PATHOGENIC M41 STRAIN REMAINS ATTENUATED BUT INDUCES PROTECTIVE IMMUNITY, 15 December 2004 (2004-12-15) *

Also Published As

Publication number Publication date
CN112996537A (zh) 2021-06-18
EA202191145A1 (ru) 2021-08-23
WO2020089164A1 (en) 2020-05-07
JP7206383B2 (ja) 2023-01-17
UA129674C2 (uk) 2025-07-02
IL282465A (en) 2021-06-30
US11224649B2 (en) 2022-01-18
CO2021005066A2 (es) 2021-04-30
AR116876A1 (es) 2021-06-23
US20200129613A1 (en) 2020-04-30
CN112996537B (zh) 2025-04-25
IL282465B1 (en) 2024-12-01
CN120290498A (zh) 2025-07-11
MX2021004907A (es) 2021-06-15
US20220265815A1 (en) 2022-08-25
EP3873516A1 (en) 2021-09-08
KR20210087058A (ko) 2021-07-09
US11744888B2 (en) 2023-09-05
JP2022512836A (ja) 2022-02-07
MY207126A (en) 2025-01-31
BR112021008440A2 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
IL282465B2 (en) 4/91 IBV vaccine with heterologous spike protein
US11999766B2 (en) Modified S1 subunit of the coronavirus spike protein
US11065328B2 (en) Vaccine against infectious bronchitis virus
IL282467B1 (en) H52 IBV assembly with heterologous spike protein
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
US11179459B1 (en) Vaccine composition for preventing human infection of SARS coronavirus and alleviating infection symptoms
US12403191B2 (en) Attenuated IBV with extended cell culture and tissue tropism
US20220213148A1 (en) Modified s2 subunit of the coronavirus spike protein
JP2013535214A (ja) 改変された伝染性喉頭気管炎ウイルス（ｉｌｔｖ）およびその使用
WO2025027551A2 (en) Ibv vaccine with heterologous dmv/1639 spike protein
EA045451B1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA045753B1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком